We are live on ! Find out more
BOLD icon

Audentes Therapeutics
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

89 hedge funds and large institutions have $768M invested in Audentes Therapeutics in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 19 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 19

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

30% more capital inflows, than outflows

Capital inflows: $119M | Capital outflows: $91.6M

10% more funds holding

Funds holding: 81 → 89 (+8)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.58% less ownership

Funds ownership: 84.83% → 82.25% (-2.6%)

Holders
89
Holders Change
+8
Holders Change %
+9.88%
% of All Funds
2.01%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
35
Reduced
19
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BOLD Hedge Fund Activity: Q4 2017 in Review

89 of the 4,421 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics (BOLD) for Q4 2017, worth a combined $768M — up 16% from $660M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new BOLD positions and 12 closed out — a net gain of 8 holders — while 35 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $31.3M. The largest seller was Adage Capital Partners, cutting an estimated $31.6M.

  • 89 institutional investors held Audentes Therapeutics (BOLD) as of Q4 2017, up from 81 in Q3 2017.
  • Funds reported $768M of Audentes Therapeutics stock for Q4 2017, up 16% quarter-over-quarter.
  • 20 funds opened new Audentes Therapeutics positions in Q4 2017 and 12 closed out, a net change of +8 holders.
  • The largest Audentes Therapeutics buyer in Q4 2017 was Fidelity Investments, an estimated $31.3M added.
  • The largest Audentes Therapeutics seller in Q4 2017 was Adage Capital Partners, an estimated $31.6M sold.

Based on aggregated 13F filings for Q4 2017.